ScoreHaematology
MGUS risk of progression (Mayo)
Stratifies the 20-year risk of progression of monoclonal gammopathy of undetermined significance using three factors.
Updated 30 October 2026
When to use it
Patients with newly diagnosed MGUS, to decide follow-up intensity and the need for bone marrow assessment.
What it needs
- Serum M protein
- Heavy-chain isotype
- Free light chain kappa/lambda ratio
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Low risk: ≈ 5 % progression at 20 years |
| 1 | Low-intermediate risk: ≈ 21 % at 20 years |
| 2 | High-intermediate risk: ≈ 37 % at 20 years |
| ≥ 3 | High risk: ≈ 58 % at 20 years |
Practical tip
Low-risk MGUS (no factors) can be followed with a review at 6 months and then every 2–3 years unless symptoms appear.
2 more practical tips in the app.
Reference
- Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106(3):812-817.
- Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121-1127.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
